---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000047"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-06-30T12:05:11+00:00"
generated_at: "2026-06-30T12:10:31.217540+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# VOICE trial interim analysis shows Vafseo superior to ESA on composite endpoint; trial stopped

## Summary
- Win odds 1.16 (95% CI 1.06-1.28, p=0.0016) for all-cause mortality/hospitalization composite.
- Hospitalizations per patient-year: 1.11 (Vafseo) vs 1.23 (ESA); incidence rate ratio 0.90 (p<0.05).
- Mortality rates similar: 8.77% vs 8.78% per 100 patient-years; rate ratio 1.00 (CI 0.718-1.391).
- Trial stopped on recommendation of Independent Data Monitoring Committee and Trial Steering Committee.
- Results replicate safety findings from INNO2VATE phase 3 program; data to be submitted for scientific meeting.

## SEC filing metadata
- accession: 0001517022-26-000047
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-06-30T12:05:11+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/0001517022-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/akba-20260630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000047
- JSON: https://secwatch.observer/filing/0001517022-26-000047.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.